The subgroup analysis of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis trial suggested increasing absolute and relative risk reduction in rhAPC treatment with greater risk of death, using higher APACHE II scores (≥25) and greater incidence of organ failure [15]. This evidence concerns the gene PROC and Sepsis.